Literature DB >> 14747446

Lack of vascular adventitial fibroblastic cells in tumour stroma of intestinal-type and solid-type gastric carcinomas.

H Nakayama1, H Enzan, E Miyazaki, N Kuroda, M Toi, M Hiroi, W Yasui.   

Abstract

AIMS: To investigate the roles of vascular adventitial fibroblastic cells in tumour stroma, the distribution of vascular adventitial fibroblastic cells was studied in gastric carcinomas.
METHODS: In total, 50 surgically resected gastric carcinomas (43 intestinal type, and seven solid type) and their normal tissues were examined. Vascular adventitial fibroblastic cells are positive for CD34 but negative for CD31. To differentiate vascular adventitial fibroblastic cells from vascular endothelial cells, immunostaining for CD34 and CD31 was performed. Immunostaining for high molecular weight caldesmon was also performed to recognise vascular media.
RESULTS: In normal gastric tissues, CD34 positive fibroblastic cells were found just outside the vascular media, namely vascular adventitial fibroblastic cells. In contrast, all of the 43 intestinal-type and seven solid-type gastric carcinomas had no vascular adventitial fibroblastic cells in the tumour stroma.
CONCLUSIONS: These results suggest that a lack of vascular adventitial fibroblastic cells is associated with tumour stroma formation in intestinal-type and solid-type gastric carcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747446      PMCID: PMC1770199          DOI: 10.1136/jcp.2003.011312

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

Review 1.  Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant.

Authors:  S Sartore; A Chiavegato; E Faggin; R Franch; M Puato; S Ausoni; P Pauletto
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

2.  Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells.

Authors:  D L Simmons; A B Satterthwaite; D G Tenen; B Seed
Journal:  J Immunol       Date:  1992-01-01       Impact factor: 5.422

Review 3.  Molecular features of CD34: a hemopoietic progenitor cell-associated molecule.

Authors:  M F Greaves; J Brown; H V Molgaard; N K Spurr; D Robertson; D Delia; D R Sutherland
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

4.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

5.  CD34 positive stromal cells in gastric adenocarcinomas.

Authors:  H Nakayama; H Enzan; E Miyazaki; N Kuroda; K Naruse; H Kiyoku; M Toi; M Hiroi
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

6.  Lack of CD34 positive stromal cells within angiomyomas (vascular leiomyomas).

Authors:  H Nakayama; H Enzan; E Miyazaki; N Kuroda; M Toi
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

7.  Alpha smooth muscle actin positive stromal cells in gastric carcinoma.

Authors:  H Nakayama; H Enzan; E Miyazaki; M Toi
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

8.  Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor.

Authors:  M Miettinen; A E Lindenmayer; A Chaubal
Journal:  Mod Pathol       Date:  1994-01       Impact factor: 7.842

  8 in total
  2 in total

1.  Presence of vascular adventitial fibroblastic cells in diffuse-type gastric carcinomas.

Authors:  H Nakayama; H Enzan; E Miyazaki; N Kuroda; M Toi; M Hiroi; W Yasui
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

2.  Vasculo-smooth muscle hamartomatous structure is linked to morphogenesis of colorectal polypoid adenoma.

Authors:  Hirofumi Nakayama; Hideaki Enzan; Wataru Yasui
Journal:  Med Mol Morphol       Date:  2014-09-09       Impact factor: 2.309

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.